|
C5ORF30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.47370000039382E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.12080000003179E-06 |
| Normal-vs-Stage2 |
9.296800E-01 |
| Normal-vs-Stage3 |
1.49310000030489E-07 |
| Normal-vs-Stage4 |
1.7686000441941E-09 |
| Stage1-vs-Stage2 |
7.181100E-04 |
| Stage1-vs-Stage3 |
3.159200E-01 |
| Stage1-vs-Stage4 |
2.341700E-03 |
| Stage2-vs-Stage3 |
2.790000E-04 |
| Stage2-vs-Stage4 |
1.56256999999105E-05 |
| Stage3-vs-Stage4 |
1.352610E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.84730003410994E-09 |
| Normal-vs-AfricanAmerican |
5.875600E-03 |
| Normal-vs-Asian |
2.78050000002139E-06 |
| Caucasian-vs-AfricanAmerican |
5.021800E-01 |
| Caucasian-vs-Asian |
9.655800E-01 |
| AfricanAmerican-vs-Asian |
5.318000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.19670000000716E-05 |
| Normal-vs-Female |
8.59719995194297E-09 |
| Male-vs-Female |
1.299610E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.50270000001773E-06 |
| Normal-vs-Age(41-60Yrs) |
9.55550000236727E-08 |
| Normal-vs-Age(61-80Yrs) |
1.658480E-03 |
| Normal-vs-Age(81-100Yrs) |
1.275600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.927800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.787200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.042200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.030300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.327400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.845000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.90999996216601E-09 |
| Classical-VS-Follicular |
4.95660001931242E-09 |
| Classical-VS-Other |
4.271000E-01 |
| Classical-VS-Normal |
1.17350000050642E-07 |
| Tall-VS-Follicular |
3.33066907387547E-16 |
| Tall-VS-Other |
5.126000E-02 |
| Tall-VS-Normal |
3.41093819855587E-12 |
| Follicular-VS-Other |
1.980010E-01 |
| Follicular-VS-Normal |
5.068600E-01 |
| Other-VS-Normal |
1.089020E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.646700E-04 |
| Normal-vs-N1 |
2.07340034030778E-10 |
| N0-vs-N1 |
1.01360000392958E-08 |
|
|
